What happened
Protein biosensors are being developed as a faster way to detect disease markers in urgent clinical settings. Sepsis is the main example because sepsis is a life-threatening condition in which delayed diagnosis can worsen outcomes.
The core idea is to detect proteins quickly and accurately in blood, where many proteins are present at the same time. That requirement makes molecular recognition the central technical challenge in protein biosensing.
How the technology evolved
Early biosensors worked well for simpler targets such as glucose. Protein detection later relied on antibodies, which can capture specific proteins but are costly and sensitive to handling and storage conditions.
A newer recognition element is the aptamer, a short synthetic DNA or RNA strand that binds a target selectively. Aptamers are cheaper, more stable, and can be produced in a laboratory.
Related current affairs
- Jitin Prasada holds bilateral meetings in Morocco on trade, investment and digital transformation
- What changes when AI moves from reading viral genomes to designing them?
- Google’s AI advantage faces its biggest test yet
- AI speech recognition model trained on 65 Indian languages and dialects released
- Parliament Question: Government schemes and missions for Artificial Intelligence, Research and Innovation
- TDB-DST supports Griva Healthcare for commercialization of indigenous AI-powered cervical cancer screening technology (GrivaVision)